1. Home
  2. PPCB vs HSCS Comparison

PPCB vs HSCS Comparison

Compare PPCB & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PPCB

Propanc Biopharma Inc.

N/A

Current Price

$1.65

Market Cap

18.1M

Sector

N/A

ML Signal

N/A

Logo Heart Test Laboratories Inc.

HSCS

Heart Test Laboratories Inc.

N/A

Current Price

$2.25

Market Cap

15.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PPCB
HSCS
Founded
2007
2007
Country
Australia
United States
Employees
N/A
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.1M
15.8M
IPO Year
2011
2022

Fundamental Metrics

Financial Performance
Metric
PPCB
HSCS
Price
$1.65
$2.25
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 125.5K
88.1K
Earning Date
11-24-2026
12-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 50.84
EPS
N/A
★ N/A
Revenue
N/A
★ $4,319.00
Revenue This Year
N/A
$295.93
Revenue Next Year
N/A
$18,321.05
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.06
$1.63
52 Week High
$6.79
$5.25

Technical Indicators

Market Signals
Indicator
PPCB
HSCS
Relative Strength Index (RSI) 64.85 34.33
Support Level $1.23 $1.84
Resistance Level $1.98 $2.76
Average True Range (ATR) 0.22 0.35
MACD 0.02 -0.08
Stochastic Oscillator 58.65 15.92

Price Performance

Historical Comparison
PPCB
HSCS

About PPCB Propanc Biopharma Inc.

Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.

About HSCS Heart Test Laboratories Inc.

HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare setting, either via the MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via the MyoVista wavECG Device.

Share on Social Networks: